Bangkok Genomics Innovation Public Company Limited (BKGI), a promising IPO stock, sold 160 million shares, reinforcing its status as a stock. Real biotech! Preparing to trade on the Stock Exchange of Thailand (SET) on March 20, 2024, “Sompop Kirasunthornphong”, Managing Director of Finansia Syrus Securities, as a financial advisor and distribution leader. We believe that the IPO price of 1.63 baht/share is an appropriate price. Moreover, it is a stock with high growth potential. Showcasing the highlights of the medical genomics industry Innovative treatment of the future. In addition, the major shareholders, both China and Thailand, voluntarily lock up partners who do not install the periodic siren according to all SET criteria for 1 year. CEO “Dr. Saowalak Dansakul” stated the market value of medical medicine of the future. Thai nomics It is expected that in 2030 it will increase to 58 billion baht, an average annual growth of 16.4%, or a 4-fold increase from 2021.
Mr. Sompop Kirasunthonphong Managing Director Finansia Syrus Securities Public Company Limited, as the financial advisor and underwriter for the initial public offering (IPO) of Bangkok Genome Company. Kas Innovation Public Company Limited (BKGI) revealed that the subscription of 160 million IPO shares of BKGI with a par value of 0.50 baht at a price of 1.63 baht per share between 12-14. March 2024 has received great interest from investors. This is because investors are confident in the fundamentals of BKGI as a stock. Thailand’s first Biotechnology to raise funds and be listed on the Stock Exchange Under the spotlight is the medical industry Genomics (Genomics), which is considered the treatment innovation of the future. Moreover, the product brand is widely known and accepted by both partners and service users.
In addition, there is an advantage from BGI Group, a world class genetic decoding service provider. is a major shareholder and own innovation Ready to transfer technology and research and also give importance to BKGI as a Flagship to support market expansion plans in the ASEAN region. This will help support the future performance of the company to grow exponentially.
In this regard, the major shareholders who are the Thai people and the BGI group have voluntarily refused to sell the remaining shares due to the prohibition period. (Period sirens) all for 1 year to build confidence for investors.
The fact that BKGI shares have received attention from investors This is because the stock price is set at an appropriate level with strong fundamentals. BKGI is preparing to trade on the Stock Exchange of Thailand (SET) on March 20, 2024, using the abbreviation “SET”. In trading as “BKGI” in the service/medical category
Dr. Saowalak Dansakul, Chief Executive Officer of Bangkok Genomics Innovation Public Company Limited (BKGI), said that the medical industry, Genomics, or the analysis of the genetic sequence of living things, life There is a trend of continued growth. The Krungthai COMPASS Research Center estimates that in 2030, the value of the Thai genomics market will reach 1.7 billion USD, or approximately 58 billion baht, with an average annual growth of 16.4%, or a 4-fold increase from 2021.
In this regard, BKGI’s revenue from reproductive health services during 2020 – 2023 has an average growth rate of 23.40% per year.
“BKGI’s business has the opportunity to grow exponentially. Because it is an industry that is in a global mega trend, BKGI can provide inspection services. and genetic screening at every age from before pregnancy, analysis of infectious disease groups and other analysis related to genetics Under the trademarks include NIFTY, VISTA, NOVA, BGI-XOME, COLOTECT, SENTIS and DNALL, which are accepted by partners and service users.”
In addition, it has strengths from having BGI, a world-class genetic decoding service provider. In transferring NGS (Next-Generation Sequencing) technology and receiving support from the BGI group in various areas to support plans to expand overseas markets in the future, which is considered New Growth of BKGI.
BKGI provides medical analysis services. By using modern scientific technology that has been transferred from the BGI group, a major shareholder. which is one of the world’s leaders in genetic decoding To be used in the development of BKGI’s analysis to ensure the Thai population has better, sustainable health in the future.
By the nature of business Can be divided into 2 types: 1. Laboratory screening and analysis service business Which is divided into 4 types: 1) Screening for genetic abnormalities in reproductive health 2) Analysis of infectious disease groups, such as testing for genetic material of the COVID-19 pathogen. and immune testing. 3) Other screening tests include screening for gene groups that are related to cancer. and screening for other inherited diseases and 4) providing technology services
2. Business selling other products such as equipment sets for collecting specimens. COVID-19 virus screening solution and reagents for testing immunity against COVID-19 and equipment sets for comprehensive genetic abnormality testing, etc., including in the future Dietary supplements will be sold. to customers who use detailed genetic decoding services for individuals According to the doctor’s advice
2024-03-14 10:26:00
#BKGI #hot #IPO #sells #million #shares #ringing #trading #bell #SET #March #showing #potential #genomic #medicine #business #future
